Skip to main content

Table 1 Clinical information of patients enrolled in this study

From: SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients

  Patient number (percentage of patients) P value*
Total patient number 33  
Age(years)   0.50
  < 65 26(78.8)  
  ≥ 65 7 (21.2)  
Gender   0.47
 Male 24(72.7)  
 Female 9(27.2)  
Location of primary tumor   0.76
 Colon 24(72.7)  
 Rectum 9(27.2)  
Number of metastatic sites   0.15
  < 3 26(84.8)  
  ≥ 3 7(15.2)  
Liver metastases   0.80
 Yes 19(54.5)  
 No 14(45.5)  
ECOG performance status   0.007**
 0 or 1 24(72.7)  
 2 9(27.2)  
Histological type   0.30
 Adenocarcinoma 28(84.8)  
 Mucinous 5(15.2)  
Previous chemotherapy treatment   0.70
 No 27 (81.8)  
 Yes 6 (18.2)  
  1. *P value was calculated according to Cox proportional hazards model between PFS and the corresponding clinical information listed in the table
  2. **Significance was found between PFS and the ECOG performance